A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
SM Hatfield, M Sitkovsky - Current opinion in pharmacology, 2016 - Elsevier
Highlights•A2AR and hypoxia in TME are important barriers that must be overcome in
cancer immunotherapy.•A2AR on immune cells are critical and non-redundant mediators of
physiological immunosuppression.•Blocking immunosuppressive A2AR-mediated signaling
may improve current cancer immunotherapy.Hypoxic and adenosine rich tumor
microenvironments represent an important barrier that must be overcome to enable T and
NK cells to reject tumors. The A2A adenosine receptor (A2AR) on activated immune cells …
cancer immunotherapy.•A2AR on immune cells are critical and non-redundant mediators of
physiological immunosuppression.•Blocking immunosuppressive A2AR-mediated signaling
may improve current cancer immunotherapy.Hypoxic and adenosine rich tumor
microenvironments represent an important barrier that must be overcome to enable T and
NK cells to reject tumors. The A2A adenosine receptor (A2AR) on activated immune cells …